In the on‐treatment samples from patients with distant tumor recurrence, we observed a higher proportion of peptidase inhibitor 16‐positive iCAF (PI16+ iCAF) cells when compared to pre‐treatment samples. This evidence concerns the gene LAP3 and neoplasm.